Heron Therapeutics, Inc. HRTX
As ofNov 16, 2026, 12:36 PM EST
- YTD
- -76.45%
- 1 year
- -72.16%
- Market cap
- 58.24M
- Revenue (ttm)
- 137.74M
- Profit margin
- -20.30%
- EPS (ttm)
- -0.11
- Shares out
- 152.10M
- YTD return
- -76.45%
- 1-year return
- -72.16%
- 50-day average
- 1.57
- Volume
- 1.38M
- Avg volume
- 4.55M
- Open
- 0.303
- Previous close
- 0.3105
- Day's range
- 0.3014 – 0.3297
- 52-week range
- 0.26 – 1.58
- Beta
- 1.81
- Price target
- 6.00 (+1859.5%)
5D +0.0385 (+13.40%)
Key statistics
- 200-day average
- 2.42
- Enterprise value
- 347.67M
- Price / sales
- 1.77
- Revenue growth
- 4.40%
- Free cash flow
- 6.76M
- Total cash
- 70.89M
- Total debt
- 178.25M
- Short % of float
- 23.40%
Fundamental scorecard
6 of 25 checks passed on HRTX’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.03 | -0.03 | 0.00 | 0.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.04 | -0.06 | -0.02 | -50.00% |
| May 7, 2024 | Mar 1, 2024 | -0.08 | -0.02 | +0.06 | +75.00% |
| Mar 12, 2024 | Dec 1, 2023 | -0.15 | -0.07 | +0.08 | +53.33% |
| Nov 14, 2023 | Sep 1, 2023 | -0.31 | -0.17 | +0.14 | +45.16% |
| Aug 14, 2023 | Jun 1, 2023 | -0.23 | -0.35 | -0.12 | -52.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 4, 2024 | Needham | reit | Buy | Buy |
| Nov 13, 2024 | Needham | main | Buy | Buy |
| Sep 25, 2024 | Needham | reit | Buy | Buy |
| Aug 7, 2024 | Needham | reit | Buy | Buy |
| Jun 13, 2024 | Rodman & Renshaw | init | — | Buy |
| May 16, 2024 | Needham | reit | Buy | Buy |
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- herontx.com
News
Deal Dispatch: Morgan Stanley Buys Vinyl Equity, Fox Completes Roku Acquisition, Children's Place Files for Chapter 11
12 Health Care Stocks Moving In Friday's Pre-Market Session
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
Heron Therapeutics, Inc. (HRTX) M&A Call Transcript
CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal
CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal
12 Health Care Stocks Moving In Monday's Intraday Session
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics Announces Third Quarter 2026 Financial Results Heron Therapeutics Q3 EPS $(0.03), Inline, Sales $35.250M Miss $37.500M Estimate
Your note
Sign in to keep a note on HRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHRISTIAN WAAGE | Director | Stock Award(Grant) | Jan 18, 2024 | 66,180 |
| COLLARD CRAIG ALEXANDER | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 17, 2024 | 290,387 |
| DISSANAIKE SHARMILA | Director | Stock Award(Grant) | Jan 18, 2024 | 69,230 |
| DUARTE IRA | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 17, 2024 | 108,001 |
| FORBES WILLIAM P | Officer | Conversion of Exercise of derivative security | Oct 17, 2024 | 103,123 |
| JOHNSON CRAIG A | Director | Stock Award(Grant) | Jan 18, 2024 | 65,820 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rubric Capital Management LP | 17.56% | 26,713,503 | 42.74M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 5.82% | 8,850,000 | 14.16M | Sep 29, 2024 |
| Vanguard Group Inc | 5.73% | 8,720,176 | 13.95M | Sep 29, 2024 |
| Blackrock Inc. | 5.61% | 8,534,567 | 13.66M | Sep 29, 2024 |
| Velan Capital Investment Management LP | 4.59% | 6,986,744 | 11.18M | Sep 29, 2024 |
| Tejara Capital Ltd | 3.49% | 5,305,816 | 8.49M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.08% | 4,683,800 | 7.49M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.00% | 3,037,660 | 4.86M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.56% | 2,376,436 | 3.80M | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Small Cap Growth Fund | 1.18% | 1,797,608 | 2.88M | Jul 30, 2024 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 0.80% | 1,212,340 | 1.94M | Jul 30, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.79% | 1,195,377 | 1.91M | Jul 30, 2024 |
